Amir Nashat, Ph.D.
Dr. Nashat is a general partner in the Boston office of Polaris Partners where he focuses on investments in the life sciences. He also serves on the board of directors of Athenix Corporation, Avila Therapeutics, Bind Biosciences, Fate Therapeutics, Living Proof, Pervasis Therapeutics, Promedior Pharmaceuticals and Selecta Biosciences. Dr. Nashat played an instrumental role in the inception of Living Proof, and Pervasis, serving as the founding president of both companies. He previously served as a director of Adnexus Therapeutics (acquired by Bristol Myers Squibb) and Hydra Biosciences and as an observer of GI Dynamics and Advion. Prior to joining Polaris, he was a Hertz fellow in chemical engineering with a minor in biology at Massachusetts Institute of Technology (MIT), where he completed his Ph.D. under the guidance of Dr. Robert Langer. During his time at MIT, Dr. Nashat also completed an internship in the London office of Goldman, Sachs & Company. He received his M.S. and B.S. in materials science and mechanical engineering at the University of California, Berkeley.